Compare Li Auto Inc (LI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Li Auto Inc trades at $11.53 (market cap $10.71B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 11.9× Li Auto Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Li Auto Inc for 101 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| LI | VRTX | |
|---|---|---|
Market Cap | $10.71B | $127.55B |
Volume | 1,781,143 | 1,487,944 |
Sector | Consumer Cyclical | Health |
52-Week High | $23.61 | $557.96 |
52-Week Low | $10.69 | $407.37 |
Typical Hold Time | 101 Days | 120 Days |
Enterprise Value | $139.58M | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $11.54, down 5.0% recently and near 52-week lows amid weak delivery numbers. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal declining revenue from $144.5B in 2024 to $112.3B in 2025 and negative net income margins. Recent news highlights September deliveries of 31,817 vehicles and new model launches like the Li i9 SUV.
Outlook remains challenging with intense EV competition and cash flow concerns, though analyst consensus suggests 32% upside to $15.18 target. Key risks include execution on new models and Chinese market volatility, while the strong balance sheet provides some stability for patient investors.
Vertex Pharmaceuticals (VRTX) trades at $510.08, up 0.88% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong 2025 results with $12B revenue and $4B net income, though recent quarterly earnings show inconsistent performance against expectations. Positive Phase 2b data for inaxaplin in kidney disease highlights pipeline progress beyond cystic fibrosis dominance.
Wall Street maintains strong bullish sentiment with 84% buy ratings and $573.50 consensus target, but risks include competitive pressures and reliance on CF franchise. The stock's premium valuation (P/E 29.31) requires continued execution on pipeline expansion to justify upside potential amid technical resistance near $515.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
